Brand Names for Daptomycin
The primary brand name for daptomycin is Cubicin, which is the original formulation approved by the FDA 1. A newer reformulated version called Cubicin RF (daptomycin RF) was approved by the FDA in 2016 for the same indications 2.
Key Distinctions Between Formulations
Cubicin RF offers improved stability and more rapid in-vial reconstitution compared to the original Cubicin formulation, while maintaining identical antibacterial coverage and clinical efficacy 2. The reformulation can be reconstituted with either sterile or bacteriostatic water for injection, providing greater flexibility in preparation 2.
Clinical Equivalence
Both formulations are bioequivalent and approved for:
- Complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria 1, 3
- Staphylococcus aureus bacteremia, including right-sided infective endocarditis caused by both methicillin-susceptible and methicillin-resistant isolates 1, 3
The choice between Cubicin and Cubicin RF is primarily based on institutional availability and pharmacy preference, as both maintain the same therapeutic profile and dosing regimens 2.